Novartis heart drug steps closer to EAMS scheme
April 23, 2015Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Novo Nordisk obesity drug is launched in the US
April 23, 2015Sales and Marketing Novo Nordisk, liraglutide, obesity, overweight, saxenda, world health organization
Novo Nordisk is rolling out its obesity drug Saxenda across the US for the treatment of obese adult patients. Saxanda …
Gilead presents new Sovaldi data
April 23, 2015Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi
Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Cristal Therapeutics hires chief business officer from Merck
April 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cristal Therapeutics, Jeroen Tonnaer, Merck
Jeroen Tonnaer has been named as the new chief business officer responsible for Cristal Therapeutics’ business development, partnering and licensing …
Study reveals true scale of falsified medicines problem
April 22, 2015Manufacturing and Production, Sales and Marketing Counterfeiting, fake, falsified medicines, health, pharma, supply chain
The full scope and prevalence of counterfeit medicines is poorly understood, according to a study of global pharma supply chains. …
Amgen files high earnings for Q1
April 22, 2015Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis
Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …
Teva faces $512m fine in generic Provigil row
April 22, 2015Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil
Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …
Two oncology successes for Pfizer
April 22, 2015Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology
Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …
Boehringer Ingelheim and Bayer ‘taking the lead’ in social media
April 22, 2015Medical Communications, Sales and Marketing Bayer, Boehringer Ingelheim, J&J and Merck, Novartis, Ogilvy Healthworld
Pharma may be finally embracing social media as a vehicle for engaging with doctors and patients, after posting more than …
EUSA Pharma appoints chief executive and director
April 22, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bryan Morton, Eusa Pharma, Göran Ando, Lee Morley
Recently-established UK-based EUSA Pharma has confirmed the appointment of Lee Morley as its chief executive and Dr Göran Ando (pictured) …
Teva moves to buy Mylan
April 21, 2015Research and Development, Sales and Marketing India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger
Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion. The …
Merck KGaA and Pfizer alliance begins lung cancer study
April 21, 2015Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo
Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …
Daiichi Sankyo to sell Sun Pharma stake
April 21, 2015Manufacturing and Production, Sales and Marketing Daiichi Sankyo, FDA, India, Ranbaxy, Sun Pharma, generics
Daiichi Sankyo is to sell off all or part of its stake in Sun Pharma and back away from the …
Novartis MS drug scores positive late-stage trial result
April 21, 2015Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis
People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …
UK firm unveils respiratory apps
April 21, 2015Medical Communications, Sales and Marketing Activ8rlives, Aseptika, SENSOR, communications, digital
Cambridgeshire-based healthcare tech firm Aseptika has made its suite of apps available to support studies in respiratory research. The UK …
Four join the ranks of IDEA Pharma
April 21, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Anastasia Liapis, Cindy Peché, IDEA Pharma, Louise Ward, Vivian Huang
IDEA Pharma has made four new appointments in Louise Ward as project manager and Cindy Peché as head of group …
Sanofi sues decision aid maker for ‘injurious falsehood’
April 20, 2015Medical Communications, Sales and Marketing Diagnosia, Sanofi, metamizole, tech
A tech start-up says it is being sued by pharma giant Sanofi for presenting facts about a drug’s side effects …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
